ArticleNature2019
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06626555 (Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection), which is not on this map. Cited by 365 papers.
0numbers the graph read from it
0cells of the map it votes in
365citing papers in PubMed
47.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06626555 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation
Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection
Who cites it
365 citing papers in PubMed, 586 citations in OpenAlex.
- HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study.Emerging microbes & infections · 2024Trial
- Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.Signal transduction and targeted therapy · 2024Trial
- HIV-Positive Liver Transplant Does not Alter the Latent Viral Reservoir in Recipients With Antiretroviral Therapy-Suppressed HIV.The Journal of infectious diseases · 2023Trial
- Brief Report: Rebound HIV Viremia With Meningoencephalitis After Antiretroviral Therapy Interruption After Allogeneic Bone Marrow Transplant.Journal of acquired immune deficiency syndromes (1999) · 2022Trial
- Short Communication: Persistence of HIV After Allogeneic Bone Marrow Transplant in a Dually Infected Individual.AIDS research and human retroviruses · 2022Trial
- SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion.Nature microbiology · 2026Article
- Article
- HIV cure: from early therapies to cutting-edge strategies.Journal of neurovirology · 2026Review
- Engineering hematopoietic stem and progenitor cells to generate red blood cells as viral traps against HIV-1.Molecular therapy. Advances · 2026Article
- Emerging CCR5-Based Therapeutic Potential of JAK/STAT Inhibitors and CCR5Δ32 Hematopoietic Stem Cell Transplantation.Viruses · 2026Review
- Development of an investigational medicinal stem cell gene therapy product to attempt curing human immunodeficiency virus infection.Scientific reports · 2026Article
- HIV cure after HCT: 7 horses seem to be on the mark.Blood advances · 2026Article
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- CRISPR/Cas9-Based Genome Editing: Understanding Differences in DNA Repair Pathways, Profiles, and Outcomes.International journal of molecular sciences · 2026Review
- Article
- From outbreak to breakthrough: Scientific and technological advances in control and cure of HIV/AIDS.hLife · 2026Article
- Review
- Acute myeloid leukemia in HIV-positive patients: biological crossroads and therapeutic Hurdles.Clinical and experimental medicine · 2026Review
- Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor.Nature microbiology · 2026Article
- Selective elimination of myeloid HIV reservoirs by targeting pro-survival pathways.The Journal of infection · 2026Article
305 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
24 authors at 11 institutions in 4 countries.
Ravindra K GuptaDivision of Infection and Immunity, UCL, London, UK. rkg20@cam.ac.uk.
Sultan Abdul-JawadDivision of Infection and Immunity, UCL, London, UK.
Laura E McCoyDivision of Infection and Immunity, UCL, London, UK.
Hoi Ping MokDepartment of Medicine, University of Cambridge, Cambridge, UK.
Dimitra PeppaMortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.
Maria SalgadoIrsiCaixa AIDS Research Institute, Badalona, Spain.
Javier Martinez-PicadoIrsiCaixa AIDS Research Institute, Badalona, Spain.
Monique NijhuisTranslational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands.
Annemarie M J WensingTranslational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands.
Helen LeeDepartment of Haematology, University of Cambridge, Cambridge, UK.
Paul GrantDepartment of Virology, UCLH, London, UK.
Eleni NastouliDepartment of Virology, UCLH, London, UK.
Jonathan LambertDepartment of Haematology, UCLH, London, UK.
Matthew PaceNuffield Department of Medicine, University of Oxford, Oxford, UK.
Fanny SalascDepartment of Medicine, University of Cambridge, Cambridge, UK.
Christopher MonitDivision of Infection and Immunity, UCL, London, UK.
Andrew J InnesDepartment of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Luke MuirDivision of Infection and Immunity, UCL, London, UK.
Laura WatersMortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.
John FraterNuffield Department of Medicine, University of Oxford, Oxford, UK.
Andrew M L LeverDepartment of Medicine, University of Cambridge, Cambridge, UK.
Simon G EdwardsMortimer Market Centre, Department of HIV, CNWL NHS Trust, London, UK.
Ian H Gabriel *Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Eduardo Olavarria *Department of Clinical Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
University College London · GBUniversity of Cambridge · GBImperial College London · GBMortimer Market Centre · GBUniversity Medical Center Utrecht · NLUniversity of Oxford · GBImperial College Healthcare NHS Trust · GBIrsiCaixa · ESNational University of Singapore · SGOxford BioMedica (United Kingdom) · GBUniversitat de Vic - Universitat Central de Catalunya · ES
Funding
Medical Research Council MR/L006588/1Medical Research Council MR/M008614/1Medical Research Council MR/M008614/2Medical Research Council MR/N02043X/1Medical Research Council MR/P011233/1Medical Research Council MR/R008698/1Wellcome Trust 108082
Abstract
A cure for HIV-1 remains unattainable as only one case has been reported, a decade ago
Indexed as
HIV-1CD4-Positive T-LymphocytesCytomegalovirusgag Gene Products, Human Immunodeficiency VirusHematopoietic Stem Cell TransplantationHIV AntibodiesHIV InfectionsHodgkin DiseaseHumansReceptors, CCR5Receptors, CXCR4Transplantation, HomologousCCR5 protein, humanCXCR4 protein, humangag Gene Products, Human Immunodeficiency VirusHIV AntibodiesReceptors, CCR5Receptors, CXCR4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06626555ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.